On the other hand, a large interindividual variation in growth response to GH treatment has been reported (5, 32, 37–40), and the response of patients with TS was relatively poor and almost equal to that of achondroplasia and lower than that of GH deficiency or Noonan syndrome judging from the first year of GH treatment in clinical trials (32). The gene discussed is GH1; the disease is Noonan syndrome.